Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Up 110.7% in January

Kazia Therapeutics Limited (NASDAQ:KZIA) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 11,800 shares, a growth of 110.7% from the December 31st total of 5,600 shares. Based on an average daily volume of 102,700 shares, the short-interest ratio is currently 0.1 days. Currently, 0.4% of the shares of the stock are short sold.

Institutional Investors Weigh In On Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. MAI Capital Management acquired a new stake in Kazia Therapeutics Limited (NASDAQ:KZIA) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned about 51.66% of Kazia Therapeutics as of its most recent filing with the SEC. Institutional investors own 30.89% of the company’s stock.

Kazia Therapeutics Trading Down 16.8 %

Shares of Kazia Therapeutics stock traded down $0.32 during midday trading on Friday, hitting $1.58. 2,199,258 shares of the company traded hands, compared to its average volume of 81,371. The firm’s fifty day moving average price is $2.81 and its 200-day moving average price is $3.82. Kazia Therapeutics has a 12 month low of $1.32 and a 12 month high of $15.80.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.